MIMEDX Group, Inc. MDXG

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Next further out: Management expects fourth quarter 2026 Adjusted EBITDA to increase sequentially and full-year net sales of $250 to $260 million. (Q4 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.

Recent results and decisions

1. Oct 28, 2026
   positive EPIEFFECT interim RCT results demonstrate clinical benefit compared to standard of care in diabetic foot ulcers.Interim RCT Results Demonstrate Clinical Benefit Associated with Use of EPIEFFECT Compared to Standard of Care Filing
2. Oct 28, 2026
   positive Federal court vacated FDA's regulatory classification of AXIOFILL and remanded to FDA for reconsideration.The Court vacated FDA's determination that AXIOFILL is not a Section 361 HCT/P because it is more than minimally manipulated and FDA's determination that AXIOFILL should be classified as a biological product rather than a medical device. Filing
3. Oct 28, 2026
   submitted Company's first two 510(k) submissions for antimicrobial xenograft and ECM particulate are in FDA review.The 510(k) designation is an important step to unlock new markets, applications, coverage and claims that we expect will grow our presence in the operating room. Filing

3 more on record.